SOM Biotech has attended the virtual workshop on the World Duchenne Awareness Day 2020

SOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020. Gal·la Pericot, R&D Manager of SOM Biotech: “The Duchenne Parent Project Spain is a valuable initiative to encourage collaboration among R&D groups that work on finding …

SOM Biotech is awarded a grant from CDTI to start clinical trials with a drug inhibitor of SARS- COV-2 replication

SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. Eravacycline is an …

SOM Biotech appoints Alain Duguet PhD as Head of Chemical Manufacturing and Control

SOM Biotech announces the appointment of Alain Duguet Ph.D. as Head of Chemical Manufacturing and Control. Alain Duguet Ph.D. has joined SOM Biotech assuming responsibility for the company´s pharmaceutical development, product manufacturing, and control and compliance with quality requirements. Alain Duguet has extensive experience in pharmaceutical development, from the setting of analytical methods, the testing …

SOM Biotech attended the BIO International Convention 2020

SOM Biotech attended the BIO International Convention 2020 in its virtual format “BIO Digital” on June 8th – 12th. The virtual gathering, one of the most relevant venues for the biotech industry worldwide, allowed SOM biotech to hold more than 70 meetings with key potential business partners and identify opportunities for future drug discovery and …

SOM Biotech keynote speaker at the Euronext webinar

SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company. Raul Insa: “As CEO and founding partner of a growing biotech company, I have led …

SOM Biotech at the BIO International Convention 2020

SOM Biotech will attend BIO International Convention 2020 in its virtual format “BIO Digital” on June 8th – 12th. The virtual gathering of the biotech industry will be one of the largest venues to be celebrated in 2020. It will allow companies to access key partners to explore opportunities and share the latest drug discovery …

The desperate use of drugs against coronavirus should be rationalized – Press release El PAÍS

Artificial Intelligence in Healthcare

SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment for infectious disease, but the situation is exceptional. “Our technology works based on chemical structure and we are looking for products available on the …

Artificial Intelligence in Healthcare Webinar

Artificial Intelligence in Healthcare

Interested in learning more about the role of Artificial Intelligence in Healthcare? Angelo Dalli, AI expert and serial tech entrepreneur, and Raúl Insa, CEO of SOM Biotech, will share their experience and thoughts on this topic at the webinar organized by EBAN – European Business Angels Network. The webinar will take place on the 12th …

We have positioned ourselves as a reference company in drug repositioning – Interview of Raúl Insa for “Actualidad Economica”

“Actualidad Economica” is the dean magazine of the Spanish economic press, founded in 1958. In the interview with the journal, Raúl tells about SOM Biotech creation, focus, and the objectives of the company. He describes the main development pipeline of SOM Biotech, and outline the expertise of its team. Raúl also reveals the most valuable …

SOM Biotech announces in vitro confirmation of three drug candidates for COVID-19 in collaboration with the Ewha Womans University

SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its artificial intelligence-based screening technology (SOMAIPRO) …